CSTL vs ICLR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CSTL · Castle Biosciences$32.52 ▼ 4.91%
ICLR · Icon PLC$204.74 ▲ 1.53%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CSTL -6.4%
- ICLR +29.8%
Head to head
| Metric | CSTL | ICLR |
|---|---|---|
| Price | $32.52 | $204.74 |
| Change today | ▼ 4.91% | ▲ 1.53% |
| Market cap | $1.00B | $15.34B |
| Return, 3 months | +0.5% | +23.3% |
| Return, year to date | -16.4% | +12.4% |
| Return, 1 year | -1.6% | +28.7% |
| P/E (TTM) | -42.8 | 35.5 |
| P/B | 2.1 | 1.7 |
| P/E percentile vs own 5y | 22nd | 39th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +20.1% | +1.2% |
| Net profit growth (YoY) | -145.5% | -64.3% |
| Gross margin | 77.3% | 23.9% |
| Operating margin | -9.0% | 10.1% |
| Net margin | -5.4% | 0.5% |
| Return on equity | -4.2% | 0.4% |
| Analyst target vs. price | +54.4% | +15.9% |
| Analyst buy share | 100% | 58% |
| RSI (14) | 43 | 66 |
| 30-day volatility | 58.0% | 59.3% |
| Max drawdown, 1 year | -57.8% | -60.5% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ICLR is the largest of the group by market value.
- ICLR has returned the most over the past year.
- CSTL carries the lowest trailing P/E.
- CSTL is growing revenue fastest.
- ICLR keeps the most profit per dollar of sales.
- CSTL has been the calmest stock over the last 30 days.